GBT Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Voxelotor for the Treatment of Sickle Cell Disease

We look forward to working with the FDA during this process, with the goal of potentially changing the treatment paradigm for SCD.